# Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

> **NCT05445609** · PHASE2 · SUSPENDED · sponsor: **Emory University** · enrollment: 10 (estimated)

## Conditions studied

- Metastatic Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **DRUG:** VLP-encapsulated TLR9 Agonist CMP-001,
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05445609
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-06-07
- **Primary completion:** 2027-06-23
- **Final completion:** 2028-06-23
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored studies with vidutolimod are being paused until further notice
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445609, "Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05445609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*